New Publication Compares Abaloparatide to Sclerostin Inhibition in CV Outcomes

A new publication involving abaloparatide appeared on July 30, 2026, in the Journal of Osteoporosis. The study is titled "Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis." It is listed as a real-world propensity score matched analysis. The publication compares cardiovascular outcomes associated with sclerostin inhibition against other anabolic therapies. Abaloparatide is referenced as one of the alternative anabolic therapies included in the comparison. No specific findings, results, or conclusions from the analysis were provided in the available event data. The publication record does not state whether outcomes favored one therapy over another. Readers interested in details of the methodology or results should consult the full text through the provided source link. This entry reflects only the existence and title of the publication as recorded, not its content or conclusions. For general background on abaloparatide, including its approved status and use, readers can refer to the compound overview.